The evolution in the use of MIBG in more than 25 years of experimental and clinical applications

Vittoria Rufini, B. Shulkin

Risultato della ricerca: Contributo in rivistaArticolo in rivista

21 Citazioni (Scopus)

Abstract

Radioiodinated metaiodobenzylguanidine (MIBG), or Iobenguane, was developed in the late 1970s at the Michigan University Medical Center for imaging the adrenal medulla and its diseases, and was rapidly extended to depict a wide range of tumors of neural crest origin. Because of its high and selective uptake and retention by these tumors, careful consideration was also given to the therapeutic potential of [(131)I]MIBG. Beside imaging and therapy of neuroendocrine tumors, the possibility of in vivo assessment of cardiac sympathetic neuronal activity led recently to a renewed interest for MIBG scintigraphy and this application is still expanding. In this paper, we review the evolution in the use of MIBG in more than 25 years of experimental and clinical applications, with attention also to the developments in radiochemistry and instrumentation. A literature search in PubMed based on ''metaiodobenzylguanidine or MIBG'' was conducted; from this analysis, it appears that the use of MIBG evolved from nearly exclusively oncology (both for diagnosis and therapy) to new applications mainly aimed to study the sympathetic neuronal integrity of the heart. Those currently exceed those about imaging of tumor diseases. We also report the geographic distribution of published papers.
Lingua originaleEnglish
pagine (da-a)341-350
Numero di pagine10
RivistaTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume52
Stato di pubblicazionePubblicato - 2008

Keywords

  • 3-Iodobenzylguanidine
  • Animals
  • Humans
  • Literature
  • Neuroendocrine Tumors
  • Radiochemistry
  • Tissue Distribution

Fingerprint

Entra nei temi di ricerca di 'The evolution in the use of MIBG in more than 25 years of experimental and clinical applications'. Insieme formano una fingerprint unica.

Cita questo